Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 1-5.doi: 10.6040/j.issn.1671-7554.0.2017.1074

   

Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer

LIU Yinhua, ZHAO Jingyi, XIN Ling   

  1. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
  • Published:2022-09-27

PDF (PC)

63

Abstract: In recent years, multigene tests have been recommended to guide decisions on the need of adjuvant chemotherapy for patients with early-stage breast cancer. The comprehensive strategy of early-stage breast cancer has come into an era, when both anatomic tumor burden and multigene test results should be taken into consideration to gain a better understanding of tumor biology and personalized treatment, in order to minimize toxic effects. In July 2017, the Journal of Clinical Oncology(JCO)published the new version of the clinical practice guideline of American Society of Clinical 山 东 大 学 学 报 (医 学 版)56卷1期 -刘荫华,等.美国临床肿瘤学会多基因检测临床实践指南更新及临床意义 \=-Oncology(ASCO)on the use of biomarkers to guide therapeutic decision for breast cancer. The guideline provided criteria of clinical utility for different patient groups, and focused on the recommendation of MammaPrint®with evidence of high quality, leading to reasonable decision-making for clinicians to avoid overtreatment.

Key words: Breast cancer, American Society of Clinical Oncology, Multigene tests, MammaPrint®,

CLC Number: 

  • R737.9
[1] Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2017, 35(24): 2838-2847.
[2] Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl~5): 8-30.
[3] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2017. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[4] Liedtk C, Thil M, Jackisch C, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017[J]. Breast Care, 2017, 12(3): 172-183.
[5] vant Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871): 530-536.
[6] van de Vijver MJ, He YD, vant Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med, 2002, 347: 1999-2009.
[7] Buyse M, Loi S, vant Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006, 98(17): 1183-1192.
[8] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Annals of Oncol, 2011, 22(8): 1736-1747.
[9] Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial[J]. Nat Clin Pract Oncol, 2006, 3(10): 540-551.
[10] Cardoso F, Vant Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial[J]. J Clin Oncol, 2008, 26(5): 729-735.
[11] Cardoso F, vant Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[12] Adjuvant! Online Web Site. http://www.adjuvantonline.com.
[13] Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2016.
[14] Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer[J]. J Clin Oncol, 2001, 19(4): 980-991.
[15] Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study[J]. Lancet Oncol, 2009, 10(11): 1070-1076.
[16] Hajage D, de Rycke Y, Bollet M, et al. External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement[J]. PLoS One, 2011, 6(11): e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.
[17] Campbell HE, Taylor MA, Harris AL, et al. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom[J]. Br J Cancer, 2009, 101(7): 1074-1084.
[18] Olivotto IA, Bajdik CD, Ravdin PM, et al. Population based validation of the prognostic model ADJUVANT! for early breast cancer[J]. J Clin Oncol, 2005, 23(12): 2716-2725.
[19] Users Guide for Adjuvant! Version 8.0, Dec 2005.
[20] Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers(EGTM)[J]. Eur J Cancer, 2017, 75: 284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28.
[21] Oncotype DX® Web Site. http://www.oncotypedx.com.
[22] EndoPredict® Web Site.http://www.endopredict.com/en/home.html.
[23] Prosigna®, PAM 50 Web Site. https://www.nanostring.com/diagnostics/prosigna.
[24] Breast Cancer Index Web Site. https://www.breastcancerindex.com.
[25] 江泽飞, 许凤锐. 乳腺癌精准医学: 热潮中的冷思考[J]. 中华外科杂志, 2017, 55(2): 90-94. JIANG Zefei, XU Fengrui. Calm thinking for precision medicine of breast cancer in the boom[J]. Chinese Journal of Surgery, 2017, 55(2): 90-94.
[1] LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[2] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[3] Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[4] LI Tao, YANG Chunlin, DU Tong, LI Heng, WANG Congcong, LI Xiaoli, DUAN Ruisheng,ZHANG Peng. Effects of diabetes mellitus on the subsets and function of NK cells in myasthenia gravis [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 31-36.
[5] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29.
[6] LI Honghao, YU Jing, CHEN Yali, GUO Shougang. Evaluation of CD4+CD25+FoxP3+ regulatory T cells and FoxP3 mRNA expression in 20 NMOSD patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 50-54.
[7] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[8] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[9] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[10] KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78.
[11] LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56bright subset of NK cells in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.
[12] YOU Xueting, TIAN Xingsong. Analysis of clinicopathological characteristics of 3 514 cases of breast cancer over 9 years [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 49-54.
[13] CAO Qianqian, JIANG Yuhua, LI Yuliang, YANG Ruijie, LIU Lu, ZHANG Xile, WANG Junjie. A dosimetric analysis of cervical metastases between radioactive 125I seeds implantation and external beam radiation therapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 55-60.
[14] LI Yanxiang, ZHANG Wenhua, YANG Feilong, FANG Liang, XU Zhonghua. The correlation between BRCA1 mRNA and protein expressions in epithelial urethra cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 91-94.
[15] LIAN Kaili, LI Yan, ZHANG Na, JIN Guiyuan, LIU Suxia. TIPE3 decreases breast cancer cell sensitivity to adriamycin by upregulating P-gp protein expression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 36-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd